|
End-of-day quote
Taiwan S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 47.80 TWD | -2.45% |
|
-3.82% | -22.53% |
| 10-07 | EirGenix Submits European Marketing Application for Breast Cancer Biosimilar | MT |
| 09-10 | EirGenix Completes Capital Reduction Following RSA Write-Off | MT |
Company Valuation: EirGenix Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 33,476 | 37,428 | 30,748 | 22,050 | 18,670 | 14,276 | - |
| Change | - | 11.81% | -17.85% | -28.29% | -15.33% | -23.54% | - |
| Enterprise Value (EV) 1 | 26,978 | 31,421 | 25,815 | 18,518 | 18,670 | 13,029 | 13,438 |
| Change | - | 16.47% | -17.84% | -28.27% | 0.82% | -30.22% | 3.14% |
| P/E | -619x | -324x | -33.5x | -31.6x | -24.6x | -31.4x | 83.9x |
| PBR | 3.21x | 3.5x | 3.07x | 2.38x | - | 1.86x | 1.82x |
| PEG | - | -3x | -0x | 1.3x | -2.4x | 0.8x | -1x |
| Capitalization / Revenue | 19.7x | 25.3x | 30.1x | 21.9x | - | 9.68x | 6.09x |
| EV / Revenue | 15.9x | 21.2x | 25.2x | 18.4x | - | 8.84x | 5.74x |
| EV / EBITDA | 220x | -243x | -32.5x | -28.4x | - | -42.4x | 31x |
| EV / EBIT | -446x | -94.2x | -25x | -19.4x | - | -22.2x | 126x |
| EV / FCF | -137x | -63.7x | -18.1x | -15x | - | -10.2x | -26.9x |
| FCF Yield | -0.73% | -1.57% | -5.52% | -6.66% | - | -9.79% | -3.72% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.18 | -0.38 | -3 | -2.28 | -2.51 | -1.52 | 0.57 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1,697 | 1,481 | 1,023 | 1,009 | - | 1,474 | 2,343 |
| EBITDA 1 | 122.4 | -129.2 | -793.1 | -652.2 | - | -307 | 434 |
| EBIT 1 | -60.52 | -333.4 | -1,032 | -953.8 | - | -586 | 107 |
| Net income 1 | -42.58 | -115.5 | -915.2 | -698.3 | -760.6 | -458 | 172 |
| Net Debt 1 | -6,498 | -6,006 | -4,933 | -3,532 | - | -1,247 | -838 |
| Reference price 2 | 111.50 | 123.00 | 100.50 | 72.00 | 61.70 | 47.80 | 47.80 |
| Nbr of stocks (in thousands) | 300,232 | 304,290 | 305,946 | 306,249 | 302,600 | 298,652 | - |
| Announcement Date | 30/03/22 | 20/03/23 | 22/03/24 | 14/03/25 | 12/03/26 | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -31.45x | 8.84x | -42.44x | - | 437M | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 25.07x | 7.53x | 15.24x | 2.01% | 426.24B | |
| Weighted average by Cap. | 37.15x | 8.83x | 22.81x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 6589 Stock
- Valuation EirGenix Inc.
Select your edition
All financial news and data tailored to specific country editions
